CRISPR-Cas9 gene repair of hematopoietic stem cells from patients with X-linked chronic granulomatous disease
The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Abstract
CRISPR-mediated gene repair of hematopoietic stem cells from patients with X-linked chronic granulomatous disease resulted in functional human leukocytes in mice after transplantation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recent studies have shown that disease-causing genetic errors can be corrected using CRISPR/Cas9 in long-term engrafting HSPCs that are preserved in downstream effector lineages15,16,24,25.”
From A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells (2018) · cites this paper as [24]
Citations
Cites
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116 · cited 1×
“CRISPR/Cas9, guided by a single-guide RNA, achieves efficient doublestranded DNA breaks (9, 10).”
BackgroundMultiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
Self-citationThe new frontier of genome engineering with CRISPR-Cas9
Doudna, J. A., & Charpentier, E. (2014) · Science · doi:10.1126/science.1258096 · Cited by 7,062
High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects
Kleinstiver, B. P., Pattanayak, V., Prew, M. S., Tsai, S. Q., Nguyen, N. T., Zheng, Z., & Joung, J. K. (2016) · Nature · doi:10.1038/nature16526 · Cited by 2,673
Engineered CRISPR-Cas9 nucleases with altered PAM specificities
Kleinstiver, B. P., Prew, M. S., Tsai, S. Q., Topkar, V. V., Nguyen, N. T., Zheng, Z., Gonzales, A. P. W., Li, Z., Peterson, R. T., Yeh, J.-R. J., et al. (2015) · Nature · doi:10.1038/nature14592 · Cited by 1,624
Cas9 as a versatile tool for engineering biology
Mali, P., Esvelt, K. M., & Church, G. M. (2013) · Nature Methods · doi:10.1038/nmeth.2649 · Cited by 1,197 · cited 1×
“CRISPR/Cas9, guided by a single-guide RNA, achieves efficient doublestranded DNA breaks (9, 10).”
BackgroundLentiviral Hematopoietic Stem Cell Gene Therapy Benefits Metachromatic Leukodystrophy
Biffi, A., Montini, E., Lorioli, L., Cesani, M., Fumagalli, F., Plati, T., Baldoli, C., Martino, S., Calabria, A., Canale, S., et al. (2013) · Science · doi:10.1126/science.1233158 · Cited by 1,180
Ott, M. G., Schmidt, M., Schwarzwaelder, K., Stein, S., Siler, U., Koehl, U., Glimm, H., Kühlcke, K., Schilz, A., Kunkel, H., et al. (2006) · Nature Medicine · doi:10.1038/nm1393 · Cited by 1,051
Lentiviral Hematopoietic Stem Cell Gene Therapy in Patients with Wiskott-Aldrich Syndrome
Aiuti, A., Biasco, L., Scaramuzza, S., Ferrua, F., Cicalese, M. P., Baricordi, C., Dionisio, F., Calabria, A., Giannelli, S., Castiello, M. C., et al. (2013) · Science · doi:10.1126/science.1233151 · Cited by 1,025
Genome editing in rice and wheat using the CRISPR/Cas system
Shan, Q., Wang, Y., Li, J., & Gao, C. (2014) · Nature Protocols · doi:10.1038/nprot.2014.157 · Cited by 763
Broadening the targeting range of Staphylococcus aureus CRISPR-Cas9 by modifying PAM recognition
Kleinstiver, B. P., Prew, M. S., Tsai, S. Q., Nguyen, N. T., Topkar, V. V., Zheng, Z., & Joung, J. K. (2015) · Nature Biotechnology · doi:10.1038/nbt.3404 · Cited by 611
Residual NADPH Oxidase and Survival in Chronic Granulomatous Disease
Kuhns, D. B., Alvord, W. G., Heller, T., Feld, J. J., Pike, K. M., Marciano, B. E., Uzel, G., DeRavin, S. S., Priel, D. A. L., Soule, B. P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007097 · Cited by 568
Self-citationTargeted genome editing in human repopulating haematopoietic stem cells
Genovese, P., Schiroli, G., Escobar, G., Di Tomaso, T., Firrito, C., Calabria, A., Moi, D., Mazzieri, R., Bonini, C., Holmes, M. C., et al. (2014) · Nature · doi:10.1038/nature13420 · Cited by 555
Stem-Cell Gene Therapy for the Wiskott–Aldrich Syndrome
Boztug, K., Schmidt, M., Schwarzer, A., Banerjee, P. P., Díez, I. A., Dewey, R. A., Böhm, M., Nowrouzi, A., Ball, C. R., Glimm, H., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003548 · Cited by 532
Correction of the sickle cell disease mutation in human hematopoietic stem/progenitor cells
Hoban, M. D., Cost, G. J., Mendel, M. C., Romero, Z., Kaufman, M. L., Joglekar, A. V., Ho, M., Lumaquin, D., Gray, D., Lill, G. R., et al. (2015) · Blood · doi:10.1182/blood-2014-12-615948 · Cited by 320 · cited 4×
“Persistence of gene repair after transplant of corrected P1 CD34 HSPCs into NSG mice Concerns about gene-edited CD34 HSPCs include whether the true repopulating CD34 HSPCs are corrected and whether treatmentassociated toxicities could inhibit either engraftment or long-term correction (15, 16).”
BackgroundInfluentialLentiviral hematopoietic stem cell gene therapy for X-linked severe combined immunodeficiency
De Ravin, S. S., Wu, X., Moir, S., Kardava, L., Anaya-O’Brien, S., Kwatemaa, N., Littel, P., Theobald, N., Choi, U., Su, L., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad8856 · Cited by 244
Self-citationSantilli, G., Almarza, E., Brendel, C., Choi, U., Beilin, C., Blundell, M. P., Haria, S., Parsley, K. L., Kinnon, C., Malech, H. L., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.226 · Cited by 144
Self-citationFlynn, R., Grundmann, A., Renz, P., Hänseler, W., James, W. S., Cowley, S. A., & Moore, M. D. (2015) · Experimental Hematology · doi:10.1016/j.exphem.2015.06.002 · Cited by 128 · cited 1×
“Although both single- and double-stranded DNA fragments have been used to promote HDR-mediated gene repair (19, 20), the former were chosen for this study.”
Dvorak, C. C., Hassan, A., Slatter, M. A., Hönig, M., Lankester, A. C., Buckley, R. H., Pulsipher, M. A., Davis, J. H., Güngör, T., Gabriel, M., et al. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.06.021 · Cited by 97 · cited 1×
“However, allogeneic transplants are complicated by graft-versus-host disease and limited donor availability (1).”
BackgroundClinical Manifestations of Disease in X-Linked Carriers of Chronic Granulomatous Disease
Battersby, A. C., Cale, C. M., Goldblatt, D., & Gennery, A. R. (2013) · Journal of Clinical Immunology · doi:10.1007/s10875-013-9939-5 · Cited by 91 · cited 1×
“Differing degrees of X chromosome inactivation in female carriers of X-CGD result in a range of disease phenotypes (18).”
BackgroundAQP8 transports NOX2-generated H2O2 across the plasma membrane to promote signaling in B cells
Bertolotti, M., Farinelli, G., Galli, M., Aiuti, A., & Sitia, R. (2016) · Journal of Leukocyte Biology · doi:10.1189/jlb.2ab0116-045r · Cited by 73 · cited 1×
“Although NOX2 is primarily associated with myeloid cell function, alterations in NOX2 activity in B lymphocytes have also been reported in CGD patients (25, 26).”
BackgroundDual-regulated Lentiviral Vector for Gene Therapy of X-linked Chronic Granulomatosis
Chiriaco, M., Farinelli, G., Capo, V., Zonari, E., Scaramuzza, S., Matteo, G. D., Sergi, L. S., Migliavacca, M., Hernández, R. J., Bombelli, F., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.87 · Cited by 67
Gene Editing Using ssODNs with Engineered Endonucleases
Chen, F., Pruett‐Miller, S. M., & Davis, G. D. (2014) · Methods in molecular biology · doi:10.1007/978-1-4939-1862-1_14 · Cited by 37 · cited 1×
“Although both single- and double-stranded DNA fragments have been used to promote HDR-mediated gene repair (19, 20), the former were chosen for this study.”
Papaioannou, I., Disterer, P., & Owen, J. S. (2009) · The Journal of Gene Medicine · doi:10.1002/jgm.1296 · Cited by 35
Doudna, J. A., & Sontheimer, E. J. (2014) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/b978-0-12-801185-0.09983-9 · Cited by 32
Moir, S. L., Ravin, S. S. D., Santich, B. H., Kim, J. Y., Posada, J. G., Ho, J., Buckner, C. M., Wang, W., Kardava, L., Garofalo, M. E., et al. (2012) · Blood · doi:10.1182/blood-2012-05-430959 · Cited by 32
Self-citationStable Gene Targeting in Human Cells Using Single-Strand Oligonucleotides with Modified Bases
Rios, X., Briggs, A. W., Christodoulou, D. C., Gorham, J., Seidman, J. G., & Church, G. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036697 · Cited by 32 · cited 2×
“Phosphorothioate modifications of a singlestranded oligodeoxynucleotide (ssODN) protect against nuclease degradation, improving activity but possibly at the cost of increasing toxicity to cell lines (21, 22).”
BackgroundMethodAn assessment of the effects of ectopic gp91phox expression in XCGD iPSC-derived neutrophils
Lin, H.-T., Masaki, H., Yamaguchi, T., Wada, T., Yachie, A., Nishimura, K., Ohtaka, M., Nakanishi, M., Nakauchi, H., & Otsu, M. (2015) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2015.46 · Cited by 28
Innate Immunity against Granulibacter bethesdensis, an Emerging Gram-Negative Bacterial Pathogen
Zarember, K. A., Marshall‐Batty, K. R., Cruz, A. R., Chu, J., Fenster, M. E., Shoffner, A. R., Rogge, L., Whitney, A. R., Czapiga, M., Song, H., et al. (2011) · Infection and Immunity · doi:10.1128/iai.05557-11 · Cited by 12
Self-citationPanch, S. R., Yau, Y. Y., Kang, E. M., Ravin, S. S. D., Malech, H. L., & Leitman, S. F. (2014) · Transfusion · doi:10.1111/trf.12830 · Cited by 11 · cited 1×
“CYBB gene mutation repair in mobilized CD34 HSPCs from X-CGD patients Next, we investigated CRISPR-mediated gene repair in mobilized CD34 HSPCs from X-CGD P1 with the C676T mutation (23).”
BackgroundSelf-citationPatching up hematopoietic stem cells
Santilli, G., & Thrasher, A. J. (2015) · Nature Biotechnology · doi:10.1038/nbt.3425 · Cited by 3 · cited 1×
“Targeted gene editing using CRISPR (clustered regularly interspaced short palindromic repeat)/Cas9 (CRISPR-associated 9) nuclease has great potential as a therapeutic approach for treating monogenic hematological diseases because of the availability of autologous HSPCs (8).”
Background
Research works printed but not linked: 1
- J. A. Doudna E. J. Sontheimer Eds. The Use of CRISPR/Cas9 ZFNs and TALENs in Generating Site-Specific Genome Alterations vol. 546 of Methods in Enzymology (Academic Press 2014) pp. xix–xx.
Cited by
Dunbar, C. E., High, K. A., Joung, J. K., Kohn, D. B., Ozawa, K., & Sadelain, M. (2018) · Science · doi:10.1126/science.aan4672 · Cited by 1,410
“However, gene correction by HDR requires donor DNA, which is more difficult to deliver, and HDR appears to be particularly inefficient in certain quiescent cell types such as long-term repopulating HSCs (68, 69), although progress is being made (70).”
Vakulskas, C. A., Dever, D. P., Rettig, G. R., Turk, R., Jacobi, A. M., Collingwood, M. A., Bode, N. M., McNeill, M. S., Yan, S., Camarena, J., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0137-0 · Cited by 782
Highly efficient therapeutic gene editing of human hematopoietic stem cells
Wu, Y., Zeng, J., Roscoe, B. P., Liu, P., Yao, Q., Lazzarotto, C. R., Clement, K., Cole, M. A., Luk, K., Baricordi, C., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0401-y · Cited by 515
CRISPR-Edited Stem Cells in a Patient with HIV and Acute Lymphocytic Leukemia
Xu, L., Wang, J., Liu, Y., Xie, L., Su, B., Mou, D., Wang, L., Liu, T., Wang, X., Zhang, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1817426 · Cited by 454
CRISPR/Cas9 genome editing in human hematopoietic stem cells.
Bak, R. O., Dever, D. P., & Porteus, M. H. (2018) · Nature Protocols · doi:10.1038/nprot.2017.143 · Cited by 319
Metadata
- Authors
- De Ravin, S. S., Li, L., Wu, X., Choi, U., Allen, C., Koontz, S., Lee, J., Theobald-Whiting, N., Chu, J., Garofalo, M., Sweeney, C., Kardava, L., Moir, S., Viley, A., Natarajan, P., Su, L., Kuhns, D., Zarember, K. A., Peshwa, M. V., & Malech, H. L.
- Affiliations
- Laboratory of Host Defenses, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
- MaxCyte (United States) (US)
- Leidos Biomedical Research Inc. (United States) (US)
- National Institutes of Health (US)
- Corresponding author
- Li, Linhong
- Malech, Harry L.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2017-01-11
- Volume
- 9
- Issue
- 372
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2577713652
- Semantic Scholar
- 531bffc692cccebccbf571ed886fd2766c50f091
- Cited by
- 258
- References
- 32
- Citations by year
- 2026: 9 · 2025: 23 · 2024: 23 · 2023: 19 · 2022: 23 · 2021: 36 · 2020: 39 · 2019: 35 · 2018: 26 · 2017: 25
- FWCI
- 13.97
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Intramural Research Program of NIAID
- NIH (Z01-A1-00644, Z01-A1-00988)
- Maryland Stem Cell Research Fund (#2015-MSCRFP-1752)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Keywords
- CRISPR/Cas9 genome editing, X-linked chronic granulomatous disease, hematopoietic stem cells, CYBB gene, gene correction, engraftment
- MeSH terms
- NADPH Oxidase 2, Animals, Cell Differentiation, DNA Repair, Female, Granulomatous Disease, Chronic, Hematopoietic Stem Cells, Humans, Mutation, Oligonucleotides, Genetic Therapy, Mutagenesis, Mice, SCID, Mice, Inbred NOD, Antigens, CD34, Mice, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.